{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:51:37Z","timestamp":1782517897361,"version":"3.54.5"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009357","name":"Burke Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.hoc.2021.08.010","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T13:17:10Z","timestamp":1635340630000},"page":"253-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Neurofibromatoses"],"prefix":"10.1016","volume":"36","author":[{"given":"Justin T.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.hoc.2021.08.010_bib1","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive cancer associations in patients with neurofibromatosis type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2021.08.010_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","author":"Legius","year":"2021","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.hoc.2021.08.010_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N","article-title":"Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects","volume":"15","author":"Messiaen","year":"2000","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.010_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<14::AID-AJMG5>3.0.CO;2-4","article-title":"Hyperactive Ras as a therapeutic target in neurofibromatosis type 1","volume":"89","author":"Weiss","year":"1999","journal-title":"Am J Med Genet"},{"issue":"2","key":"10.1016\/j.hoc.2021.08.010_bib5","first-page":"305","article-title":"An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes","volume":"53","author":"Easton","year":"1993","journal-title":"Am J Hum Genet"},{"issue":"11","key":"10.1016\/j.hoc.2021.08.010_bib6","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1212\/WNL.56.11.1433","article-title":"The clinical and diagnostic implications of mosaicism in the neurofibromatoses","volume":"56","author":"Ruggieri","year":"2001","journal-title":"Neurology"},{"issue":"Pt 6","key":"10.1016\/j.hoc.2021.08.010_bib7","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/111.6.1355","article-title":"Von Recklinghausen neurofibromatosis. A clinical and population study in South-East Wales","volume":"111","author":"Huson","year":"1988","journal-title":"Brain"},{"issue":"2 Suppl 1","key":"10.1016\/j.hoc.2021.08.010_bib8","first-page":"S5","article-title":"Cutaneous neurofibromas: current clinical and pathologic issues","volume":"91","author":"Ortonne","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.010_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/(SICI)1096-8628(19961202)66:1<7::AID-AJMG2>3.0.CO;2-R","article-title":"Neurofibromatosis type 1 and pregnancy","volume":"66","author":"Dugoff","year":"1996","journal-title":"Am J Med Genet"},{"issue":"2","key":"10.1016\/j.hoc.2021.08.010_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.13966","article-title":"Neurofibromatosis type 1: neurofibromas and sex","volume":"174","author":"Sbidian","year":"2016","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.hoc.2021.08.010_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","article-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin","volume":"12","author":"Koenig","year":"2012","journal-title":"Drugs R D"},{"issue":"2 Suppl 1","key":"10.1016\/j.hoc.2021.08.010_bib12","first-page":"S21","article-title":"Considerations for development of therapies for cutaneous neurofibroma","volume":"91","author":"Verma","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.hoc.2021.08.010_bib13","doi-asserted-by":"crossref","first-page":"e35711","DOI":"10.1371\/journal.pone.0035711","article-title":"Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis","volume":"7","author":"Plotkin","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.hoc.2021.08.010_bib14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/gcc.20921","article-title":"Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors","volume":"50","author":"Beert","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2021.08.010_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/neuonc\/noz028","article-title":"Low mutation burden and frequent loss of CDKN2A\/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas","volume":"21","author":"Pemov","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.010_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","article-title":"Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview","volume":"67","author":"Miettinen","year":"2017","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.hoc.2021.08.010_bib17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.hoc.2021.08.010_bib18","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/neuonc\/noaa053","article-title":"Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions","volume":"22","author":"Akshintala","year":"2020","journal-title":"Neuro Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2021.08.010_bib19","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2021.08.010_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","article-title":"Malignant peripheral nerve sheath tumors","volume":"19","author":"Farid","year":"2014","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.hoc.2021.08.010_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00256-019-03290-1","article-title":"Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis","volume":"49","author":"Ahlawat","year":"2020","journal-title":"Skeletal Radiol"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.010_bib22","first-page":"142","article-title":"Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1","volume":"118","author":"Dunn","year":"2013","journal-title":"J\u00a0Neurosurg"},{"issue":"5","key":"10.1016\/j.hoc.2021.08.010_bib23","doi-asserted-by":"crossref","first-page":"e20190660","DOI":"10.1542\/peds.2019-0660","article-title":"Health supervision for children with neurofibromatosis type 1","volume":"143","author":"Miller","year":"2019","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.010_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0883073817739509","article-title":"Optic pathway gliomas in neurofibromatosis type 1","volume":"33","author":"Campen","year":"2018","journal-title":"J\u00a0Child Neurol"},{"issue":"7","key":"10.1016\/j.hoc.2021.08.010_bib25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2021.08.010_bib26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/gim.2018.28","article-title":"Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"20","author":"Stewart","year":"2018","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.hoc.2021.08.010_bib27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41436-019-0651-6","article-title":"Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study","volume":"22","author":"Evans","year":"2020","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.hoc.2021.08.010_bib28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.gtc.2013.01.001","article-title":"Gastrointestinal stromal tumors","volume":"42","author":"Miettinen","year":"2013","journal-title":"Gastroenterol Clin North Am"},{"issue":"18","key":"10.1016\/j.hoc.2021.08.010_bib29","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1158\/0008-5472.CAN-09-1752","article-title":"Glomus tumors in neurofibromatosis type 1: genetic, functional, and clinical evidence of a novel association","volume":"69","author":"Brems","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.010_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","article-title":"Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought","volume":"26","author":"Evans","year":"2005","journal-title":"Otol Neurotol"},{"issue":"10","key":"10.1016\/j.hoc.2021.08.010_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jmedgenet-2017-104519","article-title":"Genetic Severity Score predicts clinical phenotype in NF2","volume":"54","author":"Halliday","year":"2017","journal-title":"J\u00a0Med Genet"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.010_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/WNL.0000000000003418","article-title":"Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis","volume":"88","author":"Smith","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.hoc.2021.08.010_bib33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00401-019-02029-5","article-title":"An update on the CNS manifestations of neurofibromatosis type 2","volume":"139","author":"Coy","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.010_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41436-019-0598-7","article-title":"Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing","volume":"22","author":"Evans","year":"2020","journal-title":"Genet Med"},{"issue":"16","key":"10.1016\/j.hoc.2021.08.010_bib35","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-08-3011","article-title":"Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2","volume":"15","author":"Evans","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2021.08.010_bib36","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1007\/s00701-020-04491-7","article-title":"Surgical management for large vestibular schwannomas: a systematic review, meta-analysis, and consensus statement on behalf of the EANS skull base section","volume":"162","author":"Starnoni","year":"2020","journal-title":"Acta Neurochir (Wien)"},{"issue":"5","key":"10.1016\/j.hoc.2021.08.010_bib37","doi-asserted-by":"crossref","first-page":"e0232421","DOI":"10.1371\/journal.pone.0232421","article-title":"Cochlear implantation outcomes in adults: a scoping review","volume":"15","author":"Boisvert","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2021.08.010_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fnins.2019.00010","article-title":"Auditory brainstem implants: recent progress and future perspectives","volume":"13","author":"Wong","year":"2019","journal-title":"Front Neurosci"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.010_bib39","first-page":"5","article-title":"Stereotactic radiosurgery for vestibular schwannoma: International Stereotactic Radiosurgery Society (ISRS) practice guideline","volume":"5","author":"Tsao","year":"2017","journal-title":"J\u00a0Radiosurg SBRT"},{"issue":"35","key":"10.1016\/j.hoc.2021.08.010_bib40","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular Schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2021.08.010_bib41","first-page":"281","article-title":"Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation","volume":"3","author":"Morris","year":"2016","journal-title":"Neurooncol Pract"},{"issue":"7","key":"10.1016\/j.hoc.2021.08.010_bib42","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/neuonc\/nor056","article-title":"Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2","volume":"13","author":"Ammoun","year":"2011","journal-title":"Neuro Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2021.08.010_bib43","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/neuonc\/nor072","article-title":"AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas","volume":"13","author":"Bush","year":"2011","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2021.08.010_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J\u00a0Neurooncol"},{"issue":"9","key":"10.1016\/j.hoc.2021.08.010_bib45","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2021.08.010_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmg.2010.085241","article-title":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset","volume":"48","author":"Smith","year":"2011","journal-title":"J\u00a0Med Genet"},{"issue":"4","key":"10.1016\/j.hoc.2021.08.010_bib47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3171\/2010.11.SPINE10350","article-title":"Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients","volume":"14","author":"Plotkin","year":"2011","journal-title":"J\u00a0Neurosurg Spine"},{"issue":"6","key":"10.1016\/j.hoc.2021.08.010_bib48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ane.12490","article-title":"Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2","volume":"133","author":"Farschtschi","year":"2016","journal-title":"Acta Neurol Scand"},{"issue":"Pt 5","key":"10.1016\/j.hoc.2021.08.010_bib49","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/brain\/awf115","article-title":"Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2","volume":"125","author":"Sperfeld","year":"2002","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.hoc.2021.08.010_bib50","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/neuonc\/nov200","article-title":"Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis","volume":"18","author":"Blakeley","year":"2016","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2021.08.010_bib51","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2018-318538","article-title":"Schwannomatosis: a genetic and epidemiological study","volume":"89","author":"Evans","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.hoc.2021.08.010_bib52","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1634\/theoncologist.2012-0162","article-title":"Clinical features of schwannomatosis: a retrospective analysis of 87 patients","volume":"17","author":"Merker","year":"2012","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.hoc.2021.08.010_bib53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ajmg.a.35760","article-title":"Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria","volume":"161A","author":"Plotkin","year":"2013","journal-title":"Am J Med Genet A"},{"issue":"2","key":"10.1016\/j.hoc.2021.08.010_bib54","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ng.2855","article-title":"Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas","volume":"46","author":"Piotrowski","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2021.08.010_bib55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2377-11-9","article-title":"SMARCB1\/INI1 germline mutations contribute to 10% of sporadic schwannomatosis","volume":"11","author":"Rousseau","year":"2011","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1016\/j.hoc.2021.08.010_bib56","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI130206","article-title":"DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis","volume":"130","author":"Rivera","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.hoc.2021.08.010_bib57","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/gim.2014.39","article-title":"A\u00a0germline missense mutation in COQ6 is associated with susceptibility to familial schwannomatosis","volume":"16","author":"Zhang","year":"2014","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.010_bib58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3171\/2015.3.SPINE141145","article-title":"Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution","volume":"24","author":"Li","year":"2016","journal-title":"J\u00a0Neurosurg Spine"},{"issue":"11","key":"10.1016\/j.hoc.2021.08.010_bib59","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1212\/01.WNL.0000163982.78900.AD","article-title":"Diagnostic criteria for schwannomatosis","volume":"64","author":"MacCollin","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.010_bib60","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajmg.a.34376","article-title":"Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis","volume":"158A","author":"Smith","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"2","key":"10.1016\/j.hoc.2021.08.010_bib61","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11060-015-1918-7","article-title":"Identification of a novel germline SMARCB1 nonsense mutation in a family manifesting both schwannomatosis and unilateral vestibular schwannoma","volume":"125","author":"Wu","year":"2015","journal-title":"J\u00a0Neurooncol"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.010_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10048-011-0300-y","article-title":"Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri","volume":"13","author":"van den Munckhof","year":"2012","journal-title":"Neurogenetics"},{"issue":"5","key":"10.1016\/j.hoc.2021.08.010_bib63","doi-asserted-by":"crossref","first-page":"e9717","DOI":"10.1097\/MD.0000000000009717","article-title":"Pain correlates with germline mutation in schwannomatosis","volume":"97","author":"Jordan","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.010_bib64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-014-1522-2","article-title":"The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study","volume":"120","author":"Vranceanu","year":"2014","journal-title":"J\u00a0Neurooncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821001131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858821001131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:19:45Z","timestamp":1760185185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858821001131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0889858821001131"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2021.08.010","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurofibromatoses","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2021.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}